Fig. 7
From: CMTM7 inhibits breast cancer progression by regulating Wnt/β-catenin signaling
TCF3 transcriptionally activated miR-182-5p. The miR-182-5p expression level after treatment with Wnt agonist 1 (A) and Wnt signaling inhibitor adavivint (B) detected by RT-qPCR. C The predictive binding site of TCF3 on the promoter region of miR-182-5p. D The miR-182-5p expression level after transfection of TCF3 expression plasmid. E The combination of TCF3 with site1 and site2 by ChIP analysis. F A dual-luciferase reporter assay was performed to validate the interaction between TCF3 and miR-182-5p. The CMTM7 expression level after treatment of Wnt agonist detected by RT-qPCR (G) and western blot (H). The CMTM7 expression level after treatment of Wnt inhibitor detected by RT-qPCR (I) and western blot (J). *p < 0.05; ***p < 0.01